Positive transcription elongation factor b activity in compensatory myocardial hypertrophy is regulated by cardiac lineage protein-1

Circulation Research

Volumn 104, Issue 12, 2009, Pages 1347-1354

  Espinoza Derout, Jorge ^a   Wagner, Michael ^a   Salciccioli, Louis ^b   Lazar, Jason M ^b   Bhaduri, Sikha ^a   Mascareno, Eduardo ^a   Chaqour, Brahim ^a   Siddiqui, M A Q ^a,b  

^a Center for Cardiovascular and Muscle Research   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

CLP 1; HEXIM1; Myocardial hypertrophy; Transcriptional elongation

Indexed keywords

CALCINEURIN; CARDIAC LINEAGE PROTEIN 1; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN INHIBITOR; RNA POLYMERASE II; UNCLASSIFIED DRUG; CCNT1 PROTEIN, MOUSE; CLP1 PROTEIN, MOUSE; CYCLINE; RNA; SLC2A1 PROTEIN, MOUSE; SLC2A4 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; ELECTROCARDIOGRAM; ENZYME ACTIVITY; HEART VENTRICLE HYPERTROPHY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RNA SYNTHESIS; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CONGESTIVE CARDIOMYOPATHY; CROSS BREEDING; DISEASE MODEL; GENETICS; HEART MUSCLE CELL; HUMAN; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALS; CARDIOMYOPATHY, DILATED; CROSSES, GENETIC; CYCLIN-DEPENDENT KINASE 9; CYCLINS; DISEASE MODELS, ANIMAL; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 4; HUMANS; MALE; MICE; MICE, KNOCKOUT; MYOCYTES, CARDIAC; RNA; RNA POLYMERASE II; TRANSCRIPTION FACTORS;

EID: 67650227687     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.191726     Document Type: Article

References (38)

1. Wagner M, Mascareno E, Siddiqui MA. Cardiac hypertrophy: signal transduction, transcriptional adaptation, and altered growth control. Ann N Y Acad Sci. 1999;874:1-10. (Pubitemid 29351925)
2. MacLellan WR, Schneider MD. Genetic dissection of cardiac growth control pathways. Annu Rev Physiol. 2000;62:289-319.
3. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intra-cellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600.
4. van Empel VP, De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res. 2004;63:487-499.
5. Olson EN, Schneider MD. Sizing up the heart: development redux in disease. Genes Dev. 2003;17:1937-1956
6. Abel ED. Glucose transport in the heart. Front Biosci. 2004;9:201-215.
7. Sano M, Abdellatif M, Oh H, Xie M, Bagella L, Giordano A, Michael LH, DeMayo FJ, Schneider MD. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med. 2002;8:1310-1317.
8. McKinsey TA, Olson EN. Cardiac hypertrophy: sorting out the circuitry. Curr Opin Genet Dev. 1999;9:267-274.
9. Lim HW, Molkentin JD. Calcineurin and human heart failure. Nat Med. 1999;5:246-247.
10. Doud SK, Pan LX, Carleton S, Marmorstein S, Siddiqui MA. Adapta-tional response in transcription factors during development of myocardial hypertrophy. J Mol Cell Cardiol. 1995;27:2359-2372.
11. Mathew S, Mascareno E, Siddiqui MA. A ternary complex of transcription factors, Nished and NFATc4, and co-activator p300 bound to an intronic sequence, intronic regulatory element, is pivotal for the up-regulation of myosin light chain-2v gene in cardiac hypertrophy J Biol Chem. 2004;279:41018-41027.
12. Johnatty SE, Dyck JR, Michael LH, Olson EN, Abdellatif M. Identification of genes regulated during mechanical load-induced cardiac hypertrophy. J Mol Cell Cardiol. 2000;32:805-815.
13. Aronow BJ, Toyokawa T, Canning A, Haghighi K, Delling U, Kranias E, Molkentin JD, Dorn GW II. Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy. Physiol Genomics. 2001; 6:19-28.
14. Zhou Q, Yik JH. The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol Mol Biol Rev. 2006;70: 646-659.
15. Orphanides G, Reinberg D. A unified theory of gene expression. Cell. 2002;108:439-451.
16. Sano M, Schneider MD. Cyclins that don't cycle-cyclin T/cyclin-dependent kinase-9 determines cardiac muscle cell size. Cell Cycle. 2003;2:99-104.
17. Yik JH, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q. Inhibition of P-TEFb (CDK9/cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol Cell. 2003;12:971-982.
18. Michels AA, Nguyen VT, Fraldi A, Labas V, Edwards M, Bonnet F, Lania L, Bensaude O. MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner. Mol Cell Biol. 2003; 23:4859-4869.
19. Ghatpande S, Goswami S, Mascareno E, Siddiqui MA. Signal trans-duction and transcriptional adaptation in embryonic heart development and during myocardial hypertrophy. Mol Cell Biochem. 1999;196:93-97.
20. Huang F, Wagner M, Siddiqui MA. Structure, expression, and functional characterization of the mouse CLP-1 gene. Gene. 2002;292:245-259.
21. Huang F, Wagner M, Siddiqui MA. Ablation of the CLP-1 gene leads to down-regulation of the HAND1 gene and abnormality of the left ventricle of the heart and fetal death. Mech Dev. 2004;121:559-572.
22. Espinoza-Derout J, Wagner M, Shahmiri K, Mascareno E, Chaqour B, Siddiqui MA. Pivotal role of cardiac lineage protein-1 (CLP-1) in tran-scriptional elongation factor P-TEFb complex formation in cardiac hypertrophy. Cardiovasc Res. 2007;75:129-138.
23. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228. (Pubitemid 28180855)
24. Semeniuk LM, Severson DL, Kryski AJ, Swirp SL, Molkentin JD, Duff HJ. Time-dependent systolic and diastolic function in mice overex-pressing calcineurin. Am J Physiol Heart Circ Physiol. 2003;284: H425-H430.
25. Sano M, Wang SC, Shirai M, Scaglia F, Xie M, Sakai S, Tanaka T, Kulkarni PA, Barger PM, Youker KA, Taffet GE, Hamamori Y, Michael LH, Craigen WJ, Schneider MD. Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. EMBO J. 2004;23: 3559-3569.
26. Takuma S, Suehiro K, Cardinale C, Hozumi T, Yano H, Shimizu J, Mullis-Jansson S, Sciacca R, Wang J, Burkhoff D, Di Tullio MR, Homma S. Anesthetic inhibition in ischemic and nonischemic murine heart: comparison with conscious echocardiographic approach. Am J Physiol Heart Circ Physiol. 2001;280:H2364-H2370.
27. Beckles DL, Mascareno E, Siddiqui MA. Inhibition of Jak2 phosphory-lation attenuates pressure overload cardiac hypertrophy. Vascul Pharmacol. 2006;45:350-357.
28. O'Keeffe B, Fong Y, Chen D, Zhou S, Zhou Q. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription. J Biol Chem. 2000;275:279-287.
29. Garber ME, Mayall TP, Suess EM, Meisenhelder J, Thompson NE, Jones KA. CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA. Mol Cell Biol. 2000;20:6958-6969.
30. Abdellatif M, Packer SE, Michael LH, Zhang D, Charng MJ, Schneider MD. A Ras-dependent pathway regulates RNA polymerase II phosphor-ylation in cardiac myocytes: implications for cardiac hypertrophy. Mol Cell Biol. 1998;18:6729-6736.
31. Katz EB, Stenbit AE, Hatton K, DePinho R, Charron MJ. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature. 1995;377:151-155.
32. Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T, Minnemann T, Boers ME, Hadro E, Oberste-Berghaus C, Quist W, Lowell BB, Ingwall JS, Kahn BB. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest. 1999;104:1703-1714.
33. Ritter O, Neyses L. The molecular basis of myocardial hypertrophy and heart failure. Trends Mol Med. 2003;9:313-321.
34. De Windt LJ, Lim HW, Bueno OF, Liang Q, Delling U, Braz JC, Glascock BJ, Kimball TF, del Monte F, Hajjar RJ, Molkentin JD. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2001;98:3322-3327.
35. Rothermel BA, McKinsey TA, Vega RB, Nicol RL, Mammen P, Yang J, Antos CL, Shelton JM, Bassel-Duby R, Olson EN, Williams RS. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo Proc Natl Acad Sci U S A. 2001;98:3328-3333.
36. Liao R, Jain M, Cui L, D'Agostino J, Aiello F, Luptak I, Ngoy S, Mortensen RM, Tian R. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation. 2002;106:2125-2131.
37. Hou T, Ray S, Brasier AR. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression. J Biol Chem. 2007;282:37091-37102.
38. Giraud S, Hurlstone A, Avril S, Coqueret O. Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene. Oncogene. 2004;23:7391-7398.